Vaccines for established cancer: overcoming the challenges posed by immune evasion (Q38769021)

6 September 2017

title

Vaccines for established cancer: overcoming the challenges posed by immune evasion (English)

1 reference

evasion of host immune response

6 September 2017

main subject

1 reference

Thorbald van Hall

4

0 references

Cornelis J. M. Melief

series ordinal

5

object named as

Cornelis J M Melief

1 reference

6 September 2017

2

Ramon Arens

1 reference

6 September 2017

Sjoerd H van der Burg

series ordinal

1

object named as

Sjoerd H van der Burg

1 reference

6 September 2017

3

Ferry Ossendorp

1 reference

6 September 2017

language of work or name

English

0 references

publication date

11 March 2016

1 reference

6 September 2017

published in

Nature Reviews Cancer

1 reference

6 September 2017

volume

16

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

219-233

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc.2016.16

6 September 2017

exact match

0 references

cites work

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Therapeutic cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Therapeutic vaccines for cancer: an overview of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

mRNA-based therapeutics--developing a new class of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Dendritic cells in cancer immunotherapy clinical trials: are we making progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Going viral with cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Central T cell tolerance: Identification of tissue-restricted autoantigens in the thymus HLA-DR peptidome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Thymic B Cells Are Licensed to Present Self Antigens for Central T Cell Tolerance Induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Frequent HLA class I loss is an early event in cervical carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The unfolded protein response (UPR)-activated transcription factor X-box-binding protein 1 (XBP1) induces microRNA-346 expression that targets the human antigen peptide transporter 1 (TAP1) mRNA and governs immune regulatory genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Altered expression of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in transformed non-lymphoid human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Novel insights into the molecular mechanisms of HLA class I abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Strategies to counteract MHC-I defects in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Nonclassical MHC class Ib-restricted cytotoxic T cells monitor antigen processing in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Deciphering and reversing tumor immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Exploring the full spectrum of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Distinct role of macrophages in different tumor microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Interleukin-6 as a therapeutic target in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The interaction of anticancer therapies with tumor-associated macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

"Re-educating" tumor-associated macrophages by targeting NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Turning tumors into vaccines: co-opting the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Targeting tumor-infiltrating macrophages to combat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tumor-specific regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

In vivo maintenance of human regulatory T cells during CD25 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Chemotherapeutic targeting of cancer-induced immunosuppressive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

CD8+ T-cell memory in tumor immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Dendritic cells: specialized and regulated antigen processing machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Structure and function of Toll receptors and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

STING and the innate immune response to nucleic acids in the cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

TLR ligand-peptide conjugate vaccines: toward clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Supramolecular peptide vaccines: tuning adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Chemotherapy Induces Macrophage Chemoattractant Protein-1 Production in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Adoptive cell transfer as personalized immunotherapy for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

CD20+ B cells: the other tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Metastases in immune-mediated dormancy: a new opportunity for targeting cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Adaptive immunity maintains occult cancer in an equilibrium state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Costimulatory and coinhibitory receptors in anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Clinical targeting of the TNF and TNFR superfamilies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Signal 3 availability limits the CD8 T cell response to a solid tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The Quantity of Autocrine IL-2 Governs the Expansion Potential of CD8+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Immunologic parameters of ultraviolet carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

High Number of Intraepithelial CD8+Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Immunotherapy for persistent viral infections and associated disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The Fate of Low Affinity Tumor-Specific CD8+ T Cells in Tumor-Bearing Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

The role of interleukin-2 during homeostasis and activation of the immune system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.16

"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy

31 March 2020

1 reference

12 December 2020

Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

1 reference

12 December 2020

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity

1 reference

12 December 2020

Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells

1 reference

12 December 2020

Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma

1 reference

12 December 2020

Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma

1 reference

12 December 2020

CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients

1 reference

12 December 2020

Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

1 reference

12 December 2020

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

1 reference

12 December 2020

Immunity to methylcholanthrene-induced sarcomas

1 reference

12 December 2020

Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma

1 reference

12 December 2020

ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2016.16

1 reference

Dimensions Publication ID

6 September 2017

1003642245

0 references

1 reference